Literature DB >> 21725512

Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).

Carmen Fierbinteanu-Braticevici1, Cristian Baicus, Laura Tribus, Raluca Papacocea.   

Abstract

AIMS: The aim of our study was to assess the clinical and biological parameters associated with Nonalcoholic steatohepatitis (NASH) and to establish the predictors of significant fibrosis in Nonalcoholic fatty liver disease (NAFLD) patients.
METHODS: We correlated clinical and biochemical parameters with histological features (simple steatosis or steatohepatitis) in 97 patients with NAFLD admitted to the University Hospital Bucharest for persistently raised aminotransferase levels. The biochemical parameters included lipid profile, glucose, liver tests and insulin. The Homeostatic Metabolic Assesment (HOMA)-index and the oxidative stress were also evaluated. Factors associated with NASH and severe fibrosis (F≥=3) were identified using the Mann-Whitney U test and multivariate analysis. The overall validity was measured using the area under receiver operating characteristic curve (AUROC) with 95% CI.
RESULTS: At univariate analysis, age, BMI, splenic longitudinal diameter (SLD), HOMA, gamma glutamyl transpeptidase, C- reactive protein (CRP), albumin and INR were significantly associated with histologically proven NASH. The multivariate analysis identified four independent predictive factors for the presence of NASH: CRP (p=0.004), SLD (p=0.018), HOMA (p=0.03) and albumin level (p=0.041). The variables independently associated with severe fibrosis were albumin (p=0.008), blood glucose (p=0.017) and BMI (p=0.048).
CONCLUSION: A predictive model that incorporates the clinical and biological parameters may identify at-risk patients with NAFLD, avoiding liver biopsy on a routine basis.

Entities:  

Mesh:

Year:  2011        PMID: 21725512

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  20 in total

1.  Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.

Authors:  Gabriela Paredes-Turrubiarte; Antonio González-Chávez; Ruy Pérez-Tamayo; Beatriz Y Salazar-Vázquez; Vito S Hernández; Nayeli Garibay-Nieto; José Manuel Fragoso; Galileo Escobedo
Journal:  Clin Exp Med       Date:  2015-04-18       Impact factor: 3.984

Review 2.  Aging of the Liver: What This Means for Patients with HIV.

Authors:  Austin W Chan; Yuval A Patel; Steve Choi
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

3.  Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients.

Authors:  Adrian T Billeter; Sarah Wloka; Rouven Behnisch; Thomas Albrecht; Stephanie Roessler; Benjamin Goeppert; Sebastian Mueller; Felix Nickel; Beat Müller
Journal:  Obes Facts       Date:  2021-08-20       Impact factor: 3.942

4.  Dynamics of serum α-fetoprotein in viral hepatitis C without hepatocellular carcinoma.

Authors:  Teodora Isac; Sebastian Isac; Simona Ioanitescu; Enyedi Mihaly; Maria-Daniela Tanasescu; Daniela Gabriela Balan; Adrian Tulin; Laura Iliescu
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

Review 5.  Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.

Authors:  Claudia Filozof; Barry J Goldstein; Richard N Williams; Arun Sanyal
Journal:  Drugs       Date:  2015-08       Impact factor: 9.546

6.  Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices.

Authors:  Satish Kumar Sadasivan; Nethra Siddaraju; Khaiser Mehdi Khan; Balamuralikrishna Vasamsetti; Nimisha R Kumar; Vibha Haridas; Madhusudhan B Reddy; Somesh Baggavalli; Anup M Oommen; Raghavendra Pralhada Rao
Journal:  Fibrogenesis Tissue Repair       Date:  2014-12-16

7.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

Authors:  Steven G Pearce; Nirav C Thosani; Jen-Jung Pan
Journal:  Biomark Res       Date:  2013-02-04

Review 8.  Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.

Authors:  Hyunwoo Oh; Dae Won Jun; Waqar K Saeed; Mindie H Nguyen
Journal:  Clin Mol Hepatol       Date:  2016-09-25

9.  Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.

Authors:  Sandra Page; Aybike Birerdinc; Michael Estep; Maria Stepanova; Arian Afendy; Emanuel Petricoin; Zobair Younossi; Vikas Chandhoke; Ancha Baranova
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

Review 10.  The Wide and Complex Field of NAFLD Biomarker Research: Trends.

Authors:  Erika Wichro; Tanja Macheiner; Jasmin Schmid; Barbara Kavsek; Karine Sargsyan
Journal:  ISRN Hepatol       Date:  2014-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.